Interleukin-1 cytokines, inflammasomes, NOD-signalosomes and autoinflammation;Interleukin-1-Zytokine, Inflammasome, NOD-Signalosome und Autoinflammation

Zeitschrift fur Rheumatologie

Volumn 68, Issue 9, 2009, Pages 712-719

  Gadola, S D ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Autoinflammation; Hereditary autoinflammatory syndromes; Inflammasomes; Interleukin 1 cytokines; NOD signalosomes

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1BETA; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR;

AUTOINFLAMMATORY DISEASE; CINCA SYNDROME; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; MUCKLE WELLS SYNDROME; PAPA SYNDROME; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; CYTOKINES; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INTERLEUKIN-1; MODELS, IMMUNOLOGICAL; NOD SIGNALING ADAPTOR PROTEINS; SIGNAL TRANSDUCTION;

EID: 70450267625     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-009-0488-5     Document Type: Review

References (28)

1. The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever.The International FMF Consortium. Cell 90:797-807
2. Hoffman HM, Mueller JL, Broide DH et al (2001 ) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 29:301-305
3. Feldmann J, Prieur AM, Quartler P et al (2002) Chronic Infantile neurological cutaneous and articular syndrome is caused by mutations in CIASI, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 71:198-203 (Pubitemid 34734724)
4. Hawkins PN, Lachmann HJ, McDermott MF (2003) lnterleukln-1-receptor antagonist in the MuckleWells syndrome. N Engl J Med 348:2583-2584
5. Hoffman HM, Rosengren S, Boyle DL et al (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364:1779-1785
6. Martinon F, Mayor A, Tschopp J (2009) The inflammasomes: guardians of the body. Annu Rev Immunol 27:229-265
7. Martinon F, Petrilli V, Mayor A et al (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237-241 (Pubitemid 43372104)
8. Gabay C, Mclnnes IB (2009) The biological and clinical Importa nee of the ,new generation'cytokines in rheumatic diseases. Arthritis ResTher 11:230
9. Dlnarello CA (2009) Immunological and Inflammatory functions of the interleukln-1 family. Ann Rev Immunol 27:519-550
10. Goldring SR (2003) Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 42(Suppl 2): 11-16
11. Fouser LA, Wright JF, Dunussi-Joannopoulos Ket al (2008) Th 17 cytokines and their emerging roles in Inflammation and autoimmunity. Immunol Rev 226:87-102
12. Fitzgerald AA, Leclercq SA, Yan A et al (2005) Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52:1794-1803 (Pubitemid 40852888)
13. Pascual V, Allantaz F, Arce E et al (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201:1479-1486 (Pubitemid 40664091)
14. Chen G, Shaw MH, Kim YG et al (2009) NOD-like receptors: role in innate immunity and inflammatory disease. Ann Rev Pathol 4:365-398
15. Ting JP, Lovering RC, Alnemri ES et al (2008) The NLR gene family: a standard nomenclature. Immunity 28:285-287
16. Chamaillard M, Hashimoto M, Horie Y et al (2003) An essential role for NODI in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 4:702-707
17. Ogura Y, Bonen DK, lnohara N et al (2001 ) A frameshift mutation In NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-606 (Pubitemid 32531409)
18. Kanazawa N, Okafuji I, Kambe N et al (2005) Early-onset sarcoidosis and CARD15 mutations with constitutive nudearfactor-kappaB activation: common genetic etiology with Blau syndrome. Blood 105:1195-1197 (Pubitemid 40170893)
19. Jin Y, Mailloux CM, Gowan K et al (2007) NALP1 in vltiligo-assoclated multiple autoimmune disease. N Engl J Med 356:1216-1225 (Pubitemid 46465597)
20. Halle A, Hornung V, Petzold GC et al (2008)The NALP3 ¡nflammasome is involved in the Innate Immune response to amyloid-beta. Nat Immunol 9:857-865
21. Dostert C, Petrilli V, Van Bruggen R et al (2008) Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320:674-677 (Pubitemid 351928351)
22. McGonagle D, Tan AL, Madden J et al (2008) Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 58:631-633 (Pubitemid 351294902)
23. Villani AC, Lemire M, Fortin G et al (2009) Common variants In the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 41:71-76
24. Rosengren S, Hoffman HM, Bugbee W et al (2005) Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann Rheum Dis 64:708-714 (Pubitemid 40559297)
25. Kastbom A, Johansson M, Verma D et al (2009) The CARD8 p.C10x polymorphism associates with the inflammatory activity in early rheumatoid arthritis. Ann Rheum Dis (Epub ahead of print)
26. Petrilli V, Papin S, Dostert C et al (2007) Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14:1583-1589 (Pubitemid 47278844)
27. Mariathasan S, Weiss DS, Newton K et al (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228-232 (Pubitemid 43372102)
28. Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1 -receptor antagonist In type 2 diabetes mellitus. N Engl J Med 356:1517-1526 (Pubitemid 46588416)